{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T05:35:32Z","timestamp":1770528932277,"version":"3.49.0"},"reference-count":50,"publisher":"Japan Atherosclerosis Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2023,1,1]]},"DOI":"10.5551\/jat.63277","type":"journal-article","created":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T22:12:50Z","timestamp":1646345570000},"page":"23-38","source":"Crossref","is-referenced-by-count":7,"title":["Additive Effects of Drinking Habits and a Susceptible Genetic Polymorphism on Cholesterol Efflux Capacity"],"prefix":"10.5551","volume":"30","author":[{"given":"Erika","family":"Matsumoto","sequence":"first","affiliation":[{"name":"Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Oniki","sequence":"additional","affiliation":[{"name":"Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ami","family":"Ota-Kontani","sequence":"additional","affiliation":[{"name":"Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri","family":"Seguchi","sequence":"additional","affiliation":[{"name":"Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Imafuku","sequence":"additional","affiliation":[{"name":"Department of Molecular Pathophysiology, Institute of Advanced Medicine, Wakayama Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Ogata","sequence":"additional","affiliation":[{"name":"Japanese Red Cross Kumamoto Health Care Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoru","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Japanese Red Cross Kumamoto Health Care Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Harada-Shiba","sequence":"additional","affiliation":[{"name":"Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute"},{"name":"Department of Molecular Pathogenesis, National Cerebral and Cardiovascular Center Research Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Saruwatari","sequence":"additional","affiliation":[{"name":"Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatsune","family":"Ogura","sequence":"additional","affiliation":[{"name":"Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute"},{"name":"Department of General Medical Science, Chiba University Graduate School of Medicine"},{"name":"Department of Metabolism and Endocrinology, Eastern Chiba Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Ko DT, Alter DA, Guo H, Koh M, Lau G, Austin PC, Booth GL, Hogg W, Jackevicius CA, Lee DS, Wijeysundera HC, Wilkins JT and Tu JV: High-Density Lipoprotein Cholesterol and Cause-Specific Mortality in Individuals Without Previous Cardiovascular Conditions: The CANHEART Study. J Am Coll Cardiol, 2016; 68: 2073-2083","DOI":"10.1016\/j.jacc.2016.08.038"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Madsen CM, Varbo A and Nordestgaard BG: Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. Eur Heart J, 2017; 38: 2478-2486","DOI":"10.1093\/eurheartj\/ehx163"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Hirata A, Sugiyama D, Watanabe M, Tamakoshi A, Iso H, Kotani K, Kiyama M, Yamada M, Ishikawa S, Murakami Y, Miura K, Ueshima H, Okamura T and Evidence for Cardiovascular Prevention from Observational Cohorts in Japan Research G: Association of extremely high levels of high-density lipoprotein cholesterol with cardiovascular mortality in a pooled analysis of 9 cohort studies including 43,407 individuals: The EPOCH-JAPAN study. J Clin Lipidol, 2018; 12: 674-684 e675","DOI":"10.1016\/j.jacl.2018.01.014"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Keene D, Price C, Shun-Shin MJ and Francis DP: Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. BMJ, 2014; 349: g4379","DOI":"10.1136\/bmj.g4379"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, Hindy G, Holm H, Ding EL, Johnson T, Schunkert H, Samani NJ, Clarke R, Hopewell JC, Thompson JF, Li M, Thorleifsson G, Newton-Cheh C, Musunuru K, Pirruccello JP, Saleheen D, Chen L, Stewart A, Schillert A, Thorsteinsdottir U, Thorgeirsson G, Anand S, Engert JC, Morgan T, Spertus J, Stoll M, Berger K, Martinelli N, Girelli D, McKeown PP, Patterson CC, Epstein SE, Devaney J, Burnett MS, Mooser V, Ripatti S, Surakka I, Nieminen MS, Sinisalo J, Lokki ML, Perola M, Havulinna A, de Faire U, Gigante B, Ingelsson E, Zeller T, Wild P, de Bakker PI, Klungel OH, Maitland-van der Zee AH, Peters BJ, de Boer A, Grobbee DE, Kamphuisen PW, Deneer VH, Elbers CC, Onland-Moret NC, Hofker MH, Wijmenga C, Verschuren WM, Boer JM, van der Schouw YT, Rasheed A, Frossard P, Demissie S, Willer C, Do R, Ordovas JM, Abecasis GR, Boehnke M, Mohlke KL, Daly MJ, Guiducci C, Burtt NP, Surti A, Gonzalez E, Purcell S, Gabriel S, Marrugat J, Peden J, Erdmann J, Diemert P, Willenborg C, Konig IR, Fischer M, Hengstenberg C, Ziegler A, Buysschaert I, Lambrechts D, Van de Werf F, Fox KA, El Mokhtari NE, Rubin D, Schrezenmeir J, Schreiber S, Schafer A, Danesh J, Blankenberg S, Roberts R, McPherson R, Watkins H, Hall AS, Overvad K, Rimm E, Boerwinkle E, Tybjaerg-Hansen A, Cupples LA, Reilly MP, Melander O, Mannucci PM, Ardissino D, Siscovick D, Elosua R, Stefansson K, O\u2019Donnell CJ, Salomaa V, Rader DJ, Peltonen L, Schwartz SM, Altshuler D and Kathiresan S: Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet, 2012; 380: 572-580","DOI":"10.1016\/S0140-6736(12)60312-2"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Rhainds D and Tardif JC: From HDL-cholesterol to HDL-function: cholesterol efflux capacity determinants. Curr Opin Lipidol, 2019; 30: 101-107","DOI":"10.1097\/MOL.0000000000000589"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, Neeland IJ, Yuhanna IS, Rader DR, de Lemos JA and Shaul PW: HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med, 2014; 371: 2383-2393","DOI":"10.1056\/NEJMoa1409065"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Nakamura M, Yamamoto Y, Imaoka W, Kuroshima T, Toragai R, Ito Y, Kanda E, E JS and Ai M: Relationships between Smoking Status, Cardiovascular Risk Factors, and Lipoproteins in a Large Japanese Population. J Atheroscler Thromb, 2021; 28: 942-953","DOI":"10.5551\/jat.56838"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Komatsu T and Uehara Y: High-Density Lipoprotein Cholesterol Efflux Capacity as a Surrogate Marker for Major Cardiac Adverse Events in Japanese Patients. J Atheroscler Thromb, 2021; 28: 692-693","DOI":"10.5551\/jat.ED157"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Talbot CPJ, Plat J, Ritsch A and Mensink RP: Determinants of cholesterol efflux capacity in humans. Prog Lipid Res, 2018; 69: 21-32","DOI":"10.1016\/j.plipres.2017.12.001"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Langer RD, Criqui MH and Reed DM: Lipoproteins and blood pressure as biological pathways for effect of moderate alcohol consumption on coronary heart disease. Circulation, 1992; 85: 910-915","DOI":"10.1161\/01.CIR.85.3.910"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Mukamal KJ, Jensen MK, Gronbaek M, Stampfer MJ, Manson JE, Pischon T and Rimm EB: Drinking frequency, mediating biomarkers, and risk of myocardial infarction in women and men. Circulation, 2005; 112: 1406-1413","DOI":"10.1161\/CIRCULATIONAHA.105.537704"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Huang S, Li J, Shearer GC, Lichtenstein AH, Zheng X, Wu Y, Jin C, Wu S and Gao X: Longitudinal study of alcohol consumption and HDL concentrations: a community-based study. Am J Clin Nutr, 2017; 105: 905-912","DOI":"10.3945\/ajcn.116.144832"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Avdulov NA, Chochina SV, Igbavboa U and Wood WG: Cholesterol efflux to high-density lipoproteins and apolipoprotein A-I phosphatidylcholine complexes is inhibited by ethanol: role of apolipoprotein structure and cooperative interaction of phosphatidylcholine and cholesterol. Biochemistry, 2000; 39: 10599-10606","DOI":"10.1021\/bi0008534"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Marmillot P, Munoz J, Patel S, Garige M, Rosse RB and Lakshman MR: Long-term ethanol consumption impairs reverse cholesterol transport function of high-density lipoproteins by depleting high-density lipoprotein sphingomyelin both in rats and in humans. Metabolism, 2007; 56: 947-953","DOI":"10.1016\/j.metabol.2007.03.003"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Koekemoer AL, Codd V, Masca NGD, Nelson CP, Musameh MD, Kaess BM, Hengstenberg C, Rader DJ and Samani NJ: Large-Scale Analysis of Determinants, Stability, and Heritability of High-Density Lipoprotein Cholesterol Efflux Capacity. Arterioscler Thromb Vasc Biol, 2017; 37: 1956-1962","DOI":"10.1161\/ATVBAHA.117.309201"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Padro T, Munoz-Garcia N, Vilahur G, Chagas P, Deya A, Antonijoan RM and Badimon L: Moderate Beer Intake and Cardiovascular Health in Overweight Individuals. Nutrients, 2018; 10: 1237","DOI":"10.3390\/nu10091237"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Perret B, Ruidavets JB, Vieu C, Jaspard B, Cambou JP, Terce F and Collet X: Alcohol consumption is associated with enrichment of high-density lipoprotein particles in polyunsaturated lipids and increased cholesterol esterification rate. Alcohol Clin Exp Res, 2002; 26: 1134-1140","DOI":"10.1111\/j.1530-0277.2002.tb02649.x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Erol A and Karpyak VM: Sex and gender-related differences in alcohol use and its consequences: Contemporary knowledge and future research considerations. Drug Alcohol Depend, 2015; 156: 1-13","DOI":"10.1016\/j.drugalcdep.2015.08.023"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Ferreira MP and Weems MK: Alcohol consumption by aging adults in the United States: health benefits and detriments. J Am Diet Assoc, 2008; 108: 1668-1676","DOI":"10.1016\/j.jada.2008.07.011"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Chen CH, Ferreira JC, Gross ER and Mochly-Rosen D: Targeting aldehyde dehydrogenase 2: new therapeutic opportunities. Physiol Rev, 2014; 94: 1-34","DOI":"10.1152\/physrev.00017.2013"},{"key":"22","unstructured":"22) Edenberg HJ: The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants. Alcohol Res Health, 2007; 30: 5-13"},{"key":"23","unstructured":"23) Mizoi Y, Yamamoto K, Ueno Y, Fukunaga T and Harada S: Involvement of genetic polymorphism of alcohol and aldehyde dehydrogenases in individual variation of alcohol metabolism. Alcohol Alcohol, 1994; 29: 707-710"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Kato N, Takeuchi F, Tabara Y, Kelly TN, Go MJ, Sim X, Tay WT, Chen CH, Zhang Y, Yamamoto K, Katsuya T, Yokota M, Kim YJ, Ong RT, Nabika T, Gu D, Chang LC, Kokubo Y, Huang W, Ohnaka K, Yamori Y, Nakashima E, Jaquish CE, Lee JY, Seielstad M, Isono M, Hixson JE, Chen YT, Miki T, Zhou X, Sugiyama T, Jeon JP, Liu JJ, Takayanagi R, Kim SS, Aung T, Sung YJ, Zhang X, Wong TY, Han BG, Kobayashi S, Ogihara T, Zhu D, Iwai N, Wu JY, Teo YY, Tai ES, Cho YS and He J: Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians. Nat Genet, 2011; 43: 531-538","DOI":"10.1038\/ng.834"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Mizuno Y, Hokimoto S, Harada E, Kinoshita K, Nakagawa K, Yoshimura M, Ogawa H and Yasue H: Variant Aldehyde Dehydrogenase 2 (ALDH2<sup>\uff0a<\/sup>2) Is a Risk Factor for Coronary Spasm and ST-Segment Elevation Myocardial Infarction. J Am Heart Assoc, 2016; 5:","DOI":"10.1161\/JAHA.116.003247"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Morita K, Saruwatari J, Miyagawa H, Uchiyashiki Y, Oniki K, Sakata M, Kajiwara A, Yoshida A, Jinnouchi H and Nakagawa K: Association between aldehyde dehydrogenase 2 polymorphisms and the incidence of diabetic retinopathy among Japanese subjects with type 2 diabetes mellitus. Cardiovasc Diabetol, 2013; 12: 132","DOI":"10.1186\/1475-2840-12-132"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Wada M, Daimon M, Emi M, Iijima H, Sato H, Koyano S, Tajima K, Kawanami T, Kurita K, Hunt SC, Hopkins PN, Kubota I, Kawata S and Kato T: Genetic association between aldehyde dehydrogenase 2 (ALDH2) variation and high-density lipoprotein cholesterol (HDL-C) among non-drinkers in two large population samples in Japan. J Atheroscler Thromb, 2008; 15: 179-184","DOI":"10.5551\/jat.E542"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Sakamoto Y, Oniki K, Kumagae N, Morita K, Otake K, Ogata Y and Saruwatari J: Beta-3-adrenergic Receptor rs4994 Polymorphism Is a Potential Biomarker for the Development of Nonalcoholic Fatty Liver Disease in Overweight\/Obese Individuals. Dis Markers, 2019; 2019: 4065327","DOI":"10.1155\/2019\/4065327"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Lin Y, Kikuchi S, Tamakoshi A, Wakai K, Kawamura T, Iso H, Ogimoto I, Yagyu K, Obata Y, Ishibashi T and Group JS: Alcohol consumption and mortality among middle-aged and elderly Japanese men and women. Ann Epidemiol, 2005; 15: 590-597","DOI":"10.1016\/j.annepidem.2004.10.010"},{"key":"30","unstructured":"30) WHO expert consulutation. 1995;"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Ogura M, Hori M and Harada-Shiba M: Association Between Cholesterol Efflux Capacity and Atherosclerotic Cardiovascular Disease in Patients With Familial Hypercholesterolemia. Arterioscler Thromb Vasc Biol, 2016; 36: 181-188","DOI":"10.1161\/ATVBAHA.115.306665"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Furuhashi M, Ogura M, Matsumoto M, Yuda S, Muranaka A, Kawamukai M, Omori A, Tanaka M, Moniwa N, Ohnishi H, Saitoh S, Harada-Shiba M, Shimamoto K and Miura T: Serum FABP5 concentration is a potential biomarker for residual risk of atherosclerosis in relation to cholesterol efflux from macrophages. Sci Rep, 2017; 7: 217","DOI":"10.1038\/s41598-017-00177-w"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Imafuku T, Watanabe H, Oniki K, Yoshida A, Kato H, Nakano T, Tokumaru K, Fujita I, Arimura N, Maeda H, Sakamoto Y, Kondo N, Morita A, Saruwatari J, Tanaka M, Matsushita K, Wada T, Fukagawa M, Otagiri M, Fitzgerald ML, Jinnouchi H and Maruyama T: Cysteinylated Albumin as a Potential Biomarker for the Progression of Kidney Disease in Patients With Type 2 Diabetes. Diabetes Care, 2021;","DOI":"10.2337\/dc20-3003"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Watanabe H, Imafuku T, Otagiri M and Maruyama T: Clinical Implications Associated With the Posttranslational Modification-Induced Functional Impairment of Albumin in Oxidative Stress-Related Diseases. J Pharm Sci, 2017; 106: 2195-2203","DOI":"10.1016\/j.xphs.2017.03.002"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Hayashi T, Suda K, Imai H and Era S: Simple and sensitive high-performance liquid chromatographic method for the investigation of dynamic changes in the redox state of rat serum albumin. J Chromatogr B Analyt Technol Biomed Life Sci, 2002; 772: 139-146","DOI":"10.1016\/S1570-0232(02)00068-5"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Higuchi S, Matsushita S, Muramatsu T, Murayama M and Hayashida M: Alcohol and aldehyde dehydrogenase genotypes and drinking behavior in Japanese. Alcohol Clin Exp Res, 1996; 20: 493-497","DOI":"10.1111\/j.1530-0277.1996.tb01080.x"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Kontush A, Lhomme M and Chapman MJ: Unraveling the complexities of the HDL lipidome. Journal of lipid research, 2013; 54: 2950-2963","DOI":"10.1194\/jlr.R036095"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Du XM, Kim MJ, Hou L, Le Goff W, Chapman MJ, Van Eck M, Curtiss LK, Burnett JR, Cartland SP, Quinn CM, Kockx M, Kontush A, Rye KA, Kritharides L and Jessup W: HDL particle size is a critical determinant of ABCA1-mediated macrophage cellular cholesterol export. Circ Res, 2015; 116: 1133-1142","DOI":"10.1161\/CIRCRESAHA.116.305485"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Badimon L, Padro T and Cubedo J: Protein changes in non-LDL-lipoproteins in familial hypercholesterolemia: implications in cardiovascular disease manifestation and outcome. Curr Opin Lipidol, 2017; 28: 427-433","DOI":"10.1097\/MOL.0000000000000441"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Niesor EJ: Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism. Curr Opin Lipidol, 2011; 22: 288-295","DOI":"10.1097\/MOL.0b013e3283475e00"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Makela SM, Jauhiainen M, Ala-Korpela M, Metso J, Lehto TM, Savolainen MJ and Hannuksela ML: HDL2 of heavy alcohol drinkers enhances cholesterol efflux from raw macrophages via phospholipid-rich HDL 2b particles. Alcohol Clin Exp Res, 2008; 32: 991-1000","DOI":"10.1111\/j.1530-0277.2008.00660.x"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Persegol L, Verges B, Foissac M, Gambert P and Duvillard L: Inability of HDL from type 2 diabetic patients to counteract the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation. Diabetologia, 2006; 49: 1380-1386","DOI":"10.1007\/s00125-006-0244-1"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) You M and Arteel GE: Effect of ethanol on lipid metabolism. J Hepatol, 2019; 70: 237-248","DOI":"10.1016\/j.jhep.2018.10.037"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Rashid S, Barrett PH, Uffelman KD, Watanabe T, Adeli K and Lewis GF: Lipolytically modified triglyceride-enriched HDLs are rapidly cleared from the circulation. Arterioscler Thromb Vasc Biol, 2002; 22: 483-487","DOI":"10.1161\/hq0302.105374"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Applebaum-Bowden D, Haffner SM, Wahl PW, Hoover JJ, Warnick GR, Albers JJ and Hazzard WR: Postheparin plasma triglyceride lipases. Relationships with very low density lipoprotein triglyceride and high density lipoprotein2 cholesterol. Arteriosclerosis, 1985; 5: 273-282","DOI":"10.1161\/01.ATV.5.3.273"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Shao B, Pennathur S, Pagani I, Oda MN, Witztum JL, Oram JF and Heinecke JW: Modifying apolipoprotein A-I by malondialdehyde, but not by an array of other reactive carbonyls, blocks cholesterol efflux by the ABCA1 pathway. J Biol Chem, 2010; 285: 18473-18484","DOI":"10.1074\/jbc.M110.118182"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Catalano G, Duchene E, Julia Z, Le Goff W, Bruckert E, Chapman MJ and Guerin M: Cellular SR-BI and ABCA1-mediated cholesterol efflux are gender-specific in healthy subjects. Journal of lipid research, 2008; 49: 635-643","DOI":"10.1194\/jlr.M700510-JLR200"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Low-Kam C, Rhainds D, Lo KS, Barhdadi A, Boule M, Alem S, Pedneault-Gagnon V, Rheaume E, Dube MP, Busseuil D, Hegele RA, Lettre G and Tardif JC: Variants at the APOE \/C1\/C2\/C4 Locus Modulate Cholesterol Efflux Capacity Independently of High-Density Lipoprotein Cholesterol. J Am Heart Assoc, 2018; 7: e009545","DOI":"10.1161\/JAHA.118.009545"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Asztalos BF, Horvath KV, Mehan M, Yokota Y and Schaefer EJ: Influence of HDL particles on cell-cholesterol efflux under various pathological conditions. Journal of lipid research, 2017; 58: 1238-1246","DOI":"10.1194\/jlr.M075648"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Thakkar H, Vincent V, Roy A, Singh S, Ramakrishnan L, Kalaivani M and Singh A: HDL functions and their interaction in patients with ST elevation myocardial infarction: a case control study. Lipids Health Dis, 2020; 19: 75","DOI":"10.1186\/s12944-020-01260-4"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/30\/1\/30_63277\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T04:49:22Z","timestamp":1715316562000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/30\/1\/30_63277\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.63277","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,1]]},"article-number":"63277"}}